May 1, 2020 / 11:17 AM / a month ago

BRIEF-Akari Therapeutics Announces Positive Topline Results From Phase II Study Of Nomacopan In Bullous Pemphigoid Patients

May 1 (Reuters) - Akari Therapeutics PLC:

* AKARI THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM FULLY RECRUITED PHASE II STUDY OF NOMACOPAN IN BULLOUS PEMPHIGOID PATIENTS

* AKARI THERAPEUTICS PLC - STUDY ACHIEVED PRIMARY ENDPOINT OF NO DRUG-RELATED SERIOUS ADVERSE EVENTS

* AKARI THERAPEUTICS PLC - STUDY ACHIEVED MAIN SECONDARY EFFICACY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below